N/A N=35 SSRI Effects on Semen Parameters in Men
Healthy
Primary: Semen Volume — 2.55 mL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=94 Medication Treatment for Depression in Nursing Home Residents
Depression
Primary: Geriatric Depression Scale (GDS) Score — 5.11; 5.03; 4.59; 4.64 units on a scale
N/A N=104 Retrospective Analysis of Outcomes With a Pharmacogenomic Algorithm
Depression · Anxiety
Primary: Number of Outpatient Visits — 13 units on a scale
N/A N=10 The Effects of Multiple Dose Fluoxetine and Metabolites on CYP1A2, CYP2C19, CYP2D6 and CYP3A4 Activity
Drug-Drug Interaction · Healthy Volunteers
Primary: Lovastatin AUC in the Presence of Fluoxetine — 170; 180 nmol*hr/L — p=>0.05
Phase 4 N=17 Aripiprazole Augmentation of SSRI Therapy in Treatment Refractory Depression
Major Depressive Disorder
Primary: Stockings of Cambridge (SOC) Mean Initial Thinking Time for 3-move Problems — -4485.50 milliseconds
Phase 4 N=30 Duloxetine Treatment in Elderly With Dysthymia
Depression · Dysthymic Disorder
Primary: Change in Hamilton Rating Scale for Depression (HAM-D, 24-item) From 0 Weeks to 12 Weeks. — 8 units on a scale — p=<0.001
Phase 4 N=139 Antidepressant Treatment at an Inner City Asthma Clinic
Depression · Asthma
Primary: Asthma Control Questionnaire (ACQ) — 1.15; 1.63; 1.39; 1.23 units on a scale
Phase 4 N=110 Antidepressant Treatment of Melancholia in Late Life
Depression · Melancholia
Primary: HAMILTON Rating Scale for DEPRESSION Range — 27.3; 27.1; 10.7; 8.4 units on a scale — p=<0.05
Phase 4 N=85 Advancing Personalized Antidepressant Treatment Using PET/MRI
Depression
Primary: Change From Baseline in Hamilton Depression Rating Scale at 8 Weeks — 11.81; 9.41 score on a scale
Phase 1 N=26 Citalopram Effects on Craving and Dopamine Receptor Availability in Alcoholics
Alcohol Dependence
Primary: Craving for Alcohol in Alcohol Dependence With Citalopram Compared to Placebo — 21; 30.4; 10.8; 10.6 score on a scale
N/A N=73 Drug Therapy to Treat Minor Depression
Depression
Primary: Efficacy Assessed Using the Inventory of Depressive Symptomatology - Clinician Rated (IDS-C) — -11.47; -9.35; -10.49 units on a scale
Phase 4 N=135 Investigation of Genetic Predictors of the Response to Selective Serotonin Re-uptake Inhibitors (SSRI) Treatment
Major Depression
Primary: Montgomery-Asberg's Depression Rating Scale — 9.2 score on a scale
N/A N=5 Venlafaxine for Depression in Alzheimer's Disease (DIADs-3)
Alzheimer's Disease · Depression
Primary: Changes in Dose Response Using the Modified Alzheimer's Disease (AD) Cooperative Study-Clinical Global Impression of Change. — 2; 0; 1; 2 Participants
Phase 4 N=130 Antidepressant Medication Plus Donepezil for Treating Late-life Depression
Depression · Dementia
Primary: Global Cognitive Performance — -0.47; -0.47; -0.23; -0.65 Z-score
N/A N=370,212 Non-interventional, Retrospective Cohort Study to Explore Antidepressant Treatment in Korea
Major Depression
Primary: Medication Possession Ratio (MPR) During First 180 Days of Treatment — 0.47; 0.49; 0.46; 0.48 Ratio
Phase 2 N=48 Double-Blind Treatment of Major Depressive Disorder With Vilazodone
Major Depressive Disorder
Primary: Montgomery-Åsberg Depression Rating Scale (MADRS) — 13.9; 12.7; 14.5; 13.2 units on a scale — p=0.342
Phase 4 N=100 Antidepressant Response in the Treatment of Depressive Symptoms and Frailty Characteristics in Older Adults
Major Depressive Disorder · Dysthymic Disorder · Depressive Disorder, NOS
Primary: Hamilton Rating Scale for Depression (HRSD) — 13.3 score on a scale
Phase 2 N=73 Optimizing the Effectiveness of Selective Serotonin Reuptake Inhibitors (SSRIs) in Treatment-Resistant Depression
Depression
Primary: Hamilton Depression Rating Scale Remission Rates — 46.1; 17.6 Percentage of Remitters HDRS17
Phase 3 N=469 Antidepressant Medication Treatment for Depression in Individuals With Chronic Heart Failure
Heart Failure, Congestive · Chronic Heart Failure · Depression
Primary: Symptoms of Depression in Congestive Heart Failure Patients With Clinical Depression After Treatment With Sertraline or Placebo — -7.1; -6.8 HDRS Change Score — p=0.89
N/A N=264 Do Serotonin Reuptake Inhibitors (SSRIs) Affect Bone Mass in Adolescents
The Skeletal Effects of SSRIs
Primary: Total Body Less Head Bone Mineral Content (TBLH BMC) Z-score (Adjusted for Age-sex-height-race) — 0.35; 0.43; 0.36; 0.44 Z score (age-sex-height-race specific)
Phase 3 N=35 Memantine Plus Es-citalopram in Elderly Depressed Patients With Cognitive Impairment
Mild Cognitive Impairment · Major Depressive Disorder · Alzheimer's Disease
Primary: Change in Selective Reminding Test - Total Immediate Recall (SRT-IR) — 7.5 units on a scale
Phase 4 N=98 Escitalopram Effects on CSF Amyloid Beta
Amyloid Beta Protein
Primary: Amyloid Beta Levels in CSF — -12.7; 6.74; -22.73; -25.63 pg/mL
Phase 3 N=70 Switching From Generic Selective Serotonin Reuptake Inhibitors (SSRIs) and Selective Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs) to Three Different Dose Initiation Strategies With Vilazodone
Major Depressive Disorder (MDD)
Primary: Change in Total MADRS Scores From Baseline to Week 8 — -24.95; -18.95; -23.89 units on a scale
N/A N=186,394 5 Alpha Reductase Inhibitors And The Risk Of Suicide And Depression
BPH · Depression · Suicide
Primary: Suicide (Based on Administrative Data Elements From Ontario Registrar General Death Database, National Ambulatory Care Reporting System, Hospital Discharge Abstracts…
Phase 4 N=108 SSRI Effects on Depression and Immunity in HIV/AIDS
Depression · HIV · AIDS
Primary: Natural Killer Cell Activity, Measured in Lytic Units [Bryant J, Day R, Whiteside TL, and Herbeman RB: Calculation of Lytic Units for the Expression of Cell-mediated…
Phase 3 N=32 The Effects of Wellbutrin (Bupropion) on Residual and Cognitive Symptoms in SSRI-treated Depression
Depression · Major Depressive Disorder · Unipolar Depression
Primary: Montgomery-Asberg Depression Rating Scale (MADRS) — 22.0; 18.0; 12.0; 14.0 units on a scale — p=.04
Phase 4 N=1,158 Study Comparing the Efficacy of Venlafaxine XR Vs. SSRIs and Conventional Antidepressants in Depressed Patients
Major Depressive Disorder
Primary: Number of Patients Achieving Remission — 554; 207 participants
Phase 4 N=42 Pharmacological Treatment of Generalized Anxiety Disorder in the Elderly
Generalized Anxiety Disorder
Primary: Comparisons of End of Study HAM-A Score Means for Sertraline 50 mg vs Placebo, Sertraline 100 mg vs Placebo, and Sertraline 50 mg vs. Sertraline 100 mg — 10.638; 10.008…
Phase 2 N=35 Antidepressant Effects of Ayahuasca: a Randomized Placebo Controlled Trial in Treatment Resistant Depression
Major Depression
Primary: Hamilton Depression Rating Scale (HAM-D) Effect Seven Days After Dosing (D7) — 16.92; 9.72 score on a scale
Phase 3 N=325 Study In Patients With Depression Not Responding to Selective Serotonin Re-uptake Inhibitors
Depressive Disorder
Primary: Change From Baseline in the Hamilton Depression Scale (HAM-D 17 Items) Total Score — 19.8; 19.4; 14.7; 14.6 Score in scale — p=0.805